✦ LIBER ✦

Biomarker-led adaptive trial blazes a trail in breast cancer

✍ Scribed by Allison, Malorye

Book ID: 109903325
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 255 KB
Volume: 28
Category: Article
ISSN: 1087-0156
DOI: 10.1038/nbt0510-383

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II chemoprevention trial design

A phase II chemoprevention trial design to identify surrogate surrogate endpoint biomarkers in breast cancer

✍ Kapil Dhingra 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 434 KB

Surrogate biomarkers for risk assessment and efficacy of potential chemopreventive agents are needed to improve the efficiency and reduce the cost of conducting chemoprevention trials. In addition to criteria of sensitivity, specificity, quantifiability, and reproducibility applicable to most potent

A randomized trial exploring the biomark

A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer

✍ O. C. Freedman; E. Amir; W. Hanna; H. Kahn; F. O’Malley; G. Dranitsaris; D. E. C 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 257 KB

Epidermal growth factor receptor and vas

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

✍ Lisa Rydén; Karin Jirström; Monica Haglund; Olle Stål; Mårten Fernö 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 267 KB